Case Report of an ABO-Matched Post-Hematopoietic Stem Cell Transplant-Associated Autoimmune Hemolytic Anemia: A Diagnostic and Therapeutic Challenge

Transplant Proc. 2025 Apr;57(3):498-501. doi: 10.1016/j.transproceed.2025.02.003. Epub 2025 Feb 26.

Abstract

Autoimmune hemolytic anemia (AIHA) is a rare complication of ABO-matched hematopoietic stem cell transplantation (HSCT). Post-HSCT AIHA is diagnosed by a positive hemolysis laboratory work-up and positive direct antiglobulin testing with usually a pan-reactive antibody in indirect antiglobulin testing. In this case report, we describe the diagnosis of post-HSCT AIHA in a 62-year-old male patient and its management with combined immunosuppressive therapy with steroids, rituximab, and intravenous immunoglobulin to achieve transfusion independence and disease remission. Post-HSCT AIHA is generally refractory to treatment but this case highlights the role of combination immunosuppressive therapies to maximize the likelihood of transfusion independence.

Publication types

  • Case Reports

MeSH terms

  • ABO Blood-Group System* / immunology
  • Anemia, Hemolytic, Autoimmune* / diagnosis
  • Anemia, Hemolytic, Autoimmune* / drug therapy
  • Anemia, Hemolytic, Autoimmune* / etiology
  • Anemia, Hemolytic, Autoimmune* / immunology
  • Anemia, Hemolytic, Autoimmune* / therapy
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Rituximab
  • Treatment Outcome

Substances

  • ABO Blood-Group System
  • Immunosuppressive Agents
  • Rituximab
  • Immunoglobulins, Intravenous
  • Antibodies, Monoclonal, Murine-Derived